Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
No public readout for Phase 2 dose expansion cohorts (ovarian, SCLC, breast) found. Trial active not recruiting, primary completion est. Mar 2026. Only Phase 1 escalation data available (18.8% PR in breast mono, framed positively), but no Phase 2-specific efficacy results or interpretation.
Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed75% confidenceGrok 4.20 (xAI)
Will the results be positive?
Only phase 1/1b monotherapy data available (PR 18.8%, DCR 61.5% in heavily pretreated HR+ mBC; well tolerated). No dedicated phase 2 efficacy readout for SCLC, ovarian, or breast expansion cohorts. Trial remains active/not recruiting with primary completion in 2026. Evidence is early, limited to one indication, and numeric/preliminary without clear positive/negative framing for the phase 2 portions.
Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No cited source provides a clear trial-specific positive or negative Phase 2 readout. NCT04553133 remains active/ongoing on trial registries, and Pfizer’s public ASCO item only says first-in-human Phase 1/2a data were being presented. That is insufficient to label this exact trial positive or negative.
Found Apr 3, 2026, 4:31 PMReviewed Apr 3, 2026, 4:46 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear public Phase 2 readout was found for this exact trial. The cited sources show NCT04553133 was still ongoing with estimated primary completion on 2026-03-30, and the public data located were early dose-escalation/monotherapy findings rather than a trial-specific Phase 2 efficacy verdict.
Found Apr 1, 2026, 7:56 PMReviewed Apr 1, 2026, 7:56 PM
ClinicalTrialsclinicaltrials.govAug 28, 2025, 12:00 AM
Study Details | NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | ClinicalTrials.gov
ClinicalTrials.gov lists NCT04553133 as Phase 2, with estimated primary completion March 30, 2026; the study assesses safety/tolerability and establishment of RP2D, indicating no completed Phase 2 efficacy readout is shown here.
Web Searchfdaaa.trialstracker.netMar 18, 2026, 12:00 AM
NCT04553133: An ongoing trial by Pfizer
Trial tracker labels NCT04553133 as an ongoing trial by Pfizer, reinforcing that the study had not yielded a finalized public outcome classification.
Web Searchs3.amazonaws.comJun 1, 2023, 12:00 AM
MEETING ABSTRACTS
ASCO abstract for NCT04553133 reported early results: PF-07104091 monotherapy was generally well tolerated and showed antitumor activity, but this was an early partial dataset, not a clear overall Phase 2 positive/negative readout for the whole trial.